AryoGen’s denosumab biosimilar has comparable efficacy and safety to Prolia

Jun 30, 2022

The results of a phase III study of Iranian biopharmaceutical company AryoGen Pharmed’s denosumab biosimilar Arylia in osteoporosis patients showed that its efficacy and safety were not inferior to Amgen’s Prolia®.

Print Page Mail Article